Provexis PLC (PXS)

Industry Drug Manufacturers - Specialty & Generic

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

0.605p

Buy

0.70p

arrow-down-0.0175p (-2.61%)

Prices updated at 12 Dec 2025, 13:00 GMT

Prices minimum 15 mins delay

Prices in GBX

Provexis PLC is engaged in developing and licensing the proprietary Fruitflow, which is a heart-health functional food ingredient for the functional food sector.

FTSE All-Share

-0.48%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

In the news

Sharecast service unavailable

Press releases

30 Oct 2025

01 Oct 2025

30 Sep 2025

07 Jan 2025

31 Dec 2024

18 Dec 2024

25 Oct 2024

30 Sep 2024

Key dates

	Forecast date
Annual general meeting	Nov 2026
Final results	Oct 2026
Annual report	Oct 2026
Half yearly results	Dec 2025

	Previous date
Annual general meeting	Nov 2025
Final results	Oct 2025
Annual report	Oct 2025
Half yearly results	Dec 2024

Company reports

31 Mar 2025

Annual Report

30 Sep 2023

Quarterly Report

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.